TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02344823

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) baseline
Description: HVPG measurement day 1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) baseline
Description: HVPG measurement day 1

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) day 7
Description: HVPG measurement day 7

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG (Hepatic venous pressure measurement) day 7
Description: HVPG measurement day 7

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionaire baseline
Description: IIEF 5 questionaire to define level of erectile dysfunction at baseline

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionaire baseline
Description: IIEF 5 questionaire to define level of erectile dysfunction at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionaire baseline
Description: IIEF 5 questionaire to define level of erectile dysfunction at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionaire baseline
Description: IIEF 5 questionaire to define level of erectile dysfunction at baseline

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionnaire at study phase end
Description: IIEF 5 questionaire to define level of erectile dysfunction at end of study phase

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionnaire at study phase end
Description: IIEF 5 questionaire to define level of erectile dysfunction at end of study phase

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionnaire at study phase end
Description: IIEF 5 questionaire to define level of erectile dysfunction at end of study phase

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IIEF 5 (International Index of Erectile Function) questionnaire at study phase end
Description: IIEF 5 questionaire to define level of erectile dysfunction at end of study phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intake once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intake once daily
Study: NCT00094445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.
Study: NCT00175227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous saline hydration + mannitol + furosemide
Description: 500 mls half-normal saline + 25g mannitol + 100 mg furosemide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous saline hydration
Description: 500 mls half-normal saline
Study: NCT04787887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Cerezyme
Description: 60IU/kg Single Intravenous Administration
Study: NCT01521000

Intervention type: DEVICE
Group type: OTHER
Intervention: Garment Sleeve
Description: compression sleeve (20 to 30 mm of Hg)

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Garment Sleeve
Description: compression sleeve (20 to 30 mm of Hg)
Study: NCT04572373

Intervention type: DIETARY_SUPPLEMENT
Intervention: SMOFlipid
Study: NCT03516565

Intervention type: OTHER
Intervention: Saliva collection
Study: NCT00589121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
Study: NCT03516565

Intervention type: OTHER
Intervention: Saliva collection

Intervention type: OTHER
Intervention: Saliva collection

Intervention type: OTHER
Intervention: GCF collection

Intervention type: OTHER
Intervention: GCF collection

Intervention type: OTHER
Intervention: GCF collection
Study: NCT03251365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC-gemcitabine
Description: • Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
Study: NCT03416348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aluminum Chloride 20% (deodorant)
Description: Aluminum Chloride (deodorant)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum Chloride 20% (deodorant)
Description: Aluminum Chloride (deodorant)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Placebo
Study: NCT02649010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enlite 3 Sensor
Description: Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enlite 3 Sensor
Description: Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
Study: NCT00860275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 50 mg, once, Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 50 mg, once, Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163 + Ketoconazole
Description: (BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Tablet, Oral, 400 mg, daily, 16 days
Study: NCT00589121

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
Study: NCT04997980

Intervention type: DRUG
Intervention: Amiodarone Injection
Study: NCT00856037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given PO
Study: NCT01423227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: One home visit plus weekly telephone calls for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-based pulmonary rehabilitation
Description: Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
Study: NCT02025959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
Study: NCT01651221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
Study: NCT01270074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo control
Description: inert liquid preparation will be given three times per week from three months of age to three years of age
Study: NCT00201643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone or Dexamethasone (2nd course of ACS)
Description: Course of Betamethasone or Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Course of Placebo (NS)
Study: NCT00860275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Tablet, Oral, 1 day 400 mg then 3 days 200 mg
Study: NCT00847808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR QD
Description: Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
Study: NCT03994354

Intervention type: PROCEDURE
Intervention: J-P drainage and cutaneous penrose drainage insertion
Description: Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
Study: NCT03814096

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
Description: Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
Study: NCT04431167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living well with Lupus
Description: The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
Study: NCT04119024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT03549390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Light-moderate intensity physical activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Light-moderate intensity physical activities
Study: NCT01419327

Intervention type: DRUG
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Description: Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
Study: NCT01791374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Study: NCT02686827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Vitamin D3 analogue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for paricalcitol)
Description: Injection fluid to mimic paricalcitol injection
Study: NCT02909764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Group
Description: Breakfast Cereal
Study: NCT03106168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of mandibular molar
Description: Patients who require extraction of mandibular molars will be submitted to surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of mandibular molar
Description: Patients who require extraction of mandibular molars will be submitted to surgery
Study: NCT04598503

Intervention type: OTHER
Intervention: full history and clinical examination
Description: For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) \[10\]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
Study: NCT00860275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163 + Fluconazole
Description: (BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
Study: NCT04224012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and respiratory therapy
Description: Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
Study: NCT02726100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMARTHealth Diabetes
Description: SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
Study: NCT01974778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Meal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meal
Description: Meal
Study: NCT03141905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sick-Day Protocol
Description: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Standard clinical care
Study: NCT02491476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracerebral micro-macroelectrodes
Description: All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
Study: NCT03066349

Intervention type: OTHER
Intervention: Questionnaires
Description: FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Description: FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
Study: NCT03152058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter\] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention.
Study: NCT06607354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grass fed lamb
Description: This study investigated the impact of consuming grass finished lamb on total blood plasma and blood plasma phospholipids (PL) FA and on cardiovascular risk factors, including heart rate, blood pressure (BP), HDL-cholesterol, LDL-cholesterol, and TAG cholesterol, in humans.
Study: NCT05146752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extremely low frequency electromagnetic fields
Description: extremely low frequency electromagnetic fields

Intervention type: OTHER
Group type: OTHER
Intervention: routine care
Description: routine care
Study: NCT03311867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethibond Suture
Description: Cerclage placement with ethibond

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolene Suture
Description: Cerclage placement with prolene
Study: NCT02781324

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Spinal Fusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Spinal Fusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Bone Scalpel
Study: NCT00971217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioural Therapy
Description: Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioural Therapy
Description: Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
Study: NCT02430558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OD-PHOENIX
Description: Decellularized, freeze-dried, irradiated osteochondral allograft
Study: NCT04084496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.